Haleon (HLN) Return on Capital Employed (2023 - 2025)

Haleon's (HLN) quarterly Return on Capital Employed came in at 10.23% in Q4 2025, down 28.75% on a QoQ basis from 14.35% in Q4 2023.

Haleon (HLN) Return on Capital Employed (2023 - 2025) Analysis & Trends

Haleon (HLN) has 2 years of Return on Capital Employed data on file, last reported at 10.23% in Q4 2025.

Quarterly Return on Capital Employed changed N/A year-over-year to 10.23% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 10.23% (changed N/A YoY) and the FY2025 annual result came in at 6.39%, down 151.0% from the prior year.
Return on Capital Employed fell to 10.23% in Q4 2025, from 14.35% in the prior quarter.
In the past five years, Return on Capital Employed ranged from a high of 14.35% in Q4 2023 to a low of 10.23% in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	6.60%
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	17.16%
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	6.07%
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	22.04%
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	-0.29%
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	18.67%
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	5.52%
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	Alkermes	8.02 Bn	7.37 Bn	397.90 Mn	3.20%

Download Data

Date	Value
Dec 31, 2025	10.23%
Dec 31, 2023	14.35%